At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Sabestomig (AZD7789)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
In Brief
A Phase 1 clinical trial evaluating Sabestomig (AZD7789) for Relapsed or Refractory Classical Hodgkin Lymphoma. Completed, enrolled 45 participants across 14 sites in 7 countries.
Detailed Summary
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Denmark, France, Italy, Spain, United Kingdom, United States
CollaboratorsParexel
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionAug 2024
Study CompletionSep 2025
TodayJul 2026
First PostedFeb 1, 2022
Enrollment StartMar 18, 2022
Primary CompletionAug 30, 2024
Study CompletionSep 4, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 4.4 years ago
Interventions
Sabestomig (AZD7789)drug
Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.